Document Type : Review Article


1 Department of Microbiology, Faculty of Basic Sciences, East-Tehran Branch, Islamic Azad University, Tehran, Iran.

2 Department of Zoology, The Assam Royal Global University, Guwahati, Assam, India.

3 Department of Biochemistry, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran


Despite the well-known high prevalence of failure in drug development, recent advancements in tissue engineering and microfabrication have helped to create microphysiological systems (MPS), or "organs-on-chips," which mimic the function of human organs. These "tissue chips" might be used for toxicity and drug screening tests, which could revolutionize the early phases of the drug development process. Additionally, they may be utilized to simulate disease conditions, supplying new instruments for deciphering disease pathologies and causes and evaluating the efficacy of novel treatments. Future clinical trials on chips might be utilized to assess novel medicines in both populations and individuals, opening the door for precision medicine. Here, we'll discuss tissue chips' diverse potential and the difficulties in developing them.


1.Van Den Berg, Albert, et al. “Personalised organs-on-chips: functional testing for precision medicine.” Lab on a Chip 19.2 (2019): 198-205.
2.Esch, Eric W., Anthony Bahinski, and Dongeun Huh. “Organs-on-chips at the frontiers of drug discovery.” Nature reviews Drug discovery 14.4 (2015): 248-260.‏
3.Low, Lucie A., and Danilo A. Tagle. “’You-on-a-chip’for precision medicine.” Expert Review of Precision Medicine and Drug Development 3.2 (2018): 137-146.
4.Low, L. A., and D. A. Tagle. “Tissue chips–innovative tools for drug development and disease modeling.” Lab on a Chip 17.18 (2017): 3026-3036.
5.Sutherland, Margaret L., Kristin M. Fabre, and Danilo A. Tagle. “The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline.” Stem cell research & therapy 4.1 (2013): 1-5.
6.Fabre, Kristin M., Christine Livingston, and Danilo A. Tagle. “Organs-on-chips (microphysiological systems): tools to expedite efficacy and toxicity testing in human tissue.” Experimental biology and medicine 239.9 (2014): 1073-1077.
7.Livingston, Christine A., Kristin M. Fabre, and Danilo A. Tagle. “Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public–private partnerships.” Computational and structural biotechnology journal 14 (2016): 207-210.
8.    DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. “Innovation in the pharmaceutical industry: new estimates of R&D costs.” Journal of health economics 47 (2016): 20-33.
9.    Cook, David, et al. “Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework.” Nature reviews Drug discovery 13.6 (2014): 419-431.
10.Seok, Junhee, et al. “Genomic responses in mouse models poorly mimic human inflammatory diseases.” Proceedings of the National Academy of Sciences 110.9 (2013): 3507-3512.
11.Huh, Dongeun, et al. “Reconstituting organ-level lung functions on a chip.” Science 328.5986 (2010): 1662-1668.‏
12.Huh, Dongeun, et al. “A human disease model of drug toxicity–induced pulmonary edema in a lung-on-a-chip microdevice.” Science translational medicine 4.159 (2012): 159ra147-159ra147.
13.Benam, Kambez H., et al. “Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip.” Cell systems 3.5 (2016): 456-466.
14.Herland, Anna, et al. “Distinct contributions of astrocytes and pericytes to neuroinflammation identified in a 3D human blood-brain barrier on a chip.” PLoS One 11.3 (2016): e0150360.
15.Shi, Yanhong, et al. “Induced pluripotent stem cell technology: a decade of progress.” Nature reviews Drug discovery 16.2 (2017): 115-130.
16.Schork, Nicholas J. “Personalized medicine: time for one-person trials.” Nature 520.7549 (2015): 609-611.‏
17.Bouvy, Jacoline C., Marie L. De Bruin, and Marc A. Koopmanschap. “Epidemiology of adverse drug reactions in Europe: a review of recent observational studies.” Drug safety 38.5 (2015): 437-453.
18.Ashley, Euan A. “Towards precision medicine.” Nature Reviews Genetics 17.9 (2016): 507-522.
19.Woodruff, Prescott G., et al. “Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.” The Lancet 385.9979 (2015): 1789-1798.
20.Skardal, Aleksander, Thomas Shupe, and Anthony Atala. “Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling.” Drug discovery today 21.9 (2016): 1399-1411.
21.Low, L. A., and D. A. Tagle. “Tissue chips–innovative tools for drug development and disease modeling.” Lab on a Chip 17.18 (2017): 3026-3036.‏
22.Clark, Amanda M., et al. “Liver metastases: Microenvironments and ex-vivo models.” Experimental Biology and Medicine 241.15 (2016): 1639-1652.
23.Clark, Amanda M., et al. “A microphysiological system model of therapy for liver micrometastases.” Experimental biology and medicine 239.9 (2014): 1170-1179.
24.Ghajari, Ghazal et al. “The association between testicular toxicity induced by Li2Co3 and protective effect of Ganoderma lucidum: Alteration of Bax & c-Kit genes expression.” Tissue & cell vol. 72 (2021): 101552.
25.Kim, Hyun Jung, et al. “Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow.” Lab on a Chip 12.12 (2012): 2165-2174.
26.Villenave, Remi, et al. “Human gut-on-a-chip supports polarized infection of coxsackie B1 virus in vitro.” PloS one 12.2 (2017): e0169412.
27.Ghajari, Ghazal, Arefe Heydari, and Masoud Ghorbani. “Mesenchymal stem cell-based therapy and female infertility: limitations and advances.” Current Stem Cell Research & Therapy (2022).
28.Fajgenbaum, David C., et al. “The collaborative network approach: a new framework to accelerate Castleman’s disease and other rare disease research.” The Lancet Haematology 3.4 (2016): e150-e152.
29.Low, Lucie A., and Danilo A. Tagle. “Tissue chips to aid drug development and modeling for rare diseases.” Expert opinion on orphan drugs 4.11 (2016): 1113-1121.
30.Wang, Gang, et al. “Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.” Nature medicine 20.6 (2014): 616-623.
31.Blumenrath, Sandra H., et al. “Tackling rare diseases: Clinical trials on chips.” Experimental Biology and Medicine 245.13 (2020): 1155-1162. Mello, Camilly P. Pires, et al. “A human-on-a-chip approach to tackling rare diseases.” Drug discovery today 24.11 (2019): 2139-2151.
33.Sun, Wujin, et al. “Engineering precision medicine.” Advanced Science 6.1 (2019): 1801039.
34.Haque, Muhammad R., et al. “Organ-chip models: opportunities for precision medicine in pancreatic cancer.” Cancers 13.17 (2021): 4487.
35.Piri-Gharaghie, Tohid, Abbas Doosti, and Seyed Abbas Mirzaei. “Fabrication and characterization of pcDNA3. 1 (+) location within chitosan/nanoparticles complexes for enhanced gene delivery.” Iranian Journal of Biotechnology 20.3 (2022): 88-100.
36.Nestor, Colm E., et al. “Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems.” Genome biology 16.1 (2015): 1-17.
37.Musah, Samira, et al. “Directed differentiation of human induced pluripotent stem cells into mature kidney podocytes and establishment of a Glomerulus Chip.” Nature protocols 13.7 (2018): 1662-1685.
38.Horvath, Peter, et al. “Screening out irrelevant cell-based models of disease.” Nature reviews Drug discovery 15.11 (2016): 751-769.
39.Workman, Michael J., et al. “Enhanced utilization of induced pluripotent stem cell–derived human intestinal organoids using microengineered chips.” Cellular and molecular gastroenterology and hepatology 5.4 (2018): 669-677.
40.Cochrane, Amy, et al. “Advanced in vitro models of vascular biology: human induced pluripotent stem cells and organ-on-chip technology.” Advanced drug delivery reviews 140 (2019): 68-77.
41.Warren, Curtis R., et al. “Induced pluripotent stem cell differentiation enables functional validation of GWAS variants in metabolic disease.” Cell Stem Cell 20.4 (2017): 547-557.
42.Low, Lucie A., et al. “Organs-on-chips: into the next decade.” Nature Reviews Drug Discovery 20.5 (2021): 345-361.
43.Yan, Mou, et al. “On-chip valley topological materials for elastic wave manipulation.” Nature Materials 17.11 (2018): 993-998.
44.Markov, Dmitry A., et al. “Variation in diffusion of gases through PDMS due to plasma surface treatment and storage conditions.” Biomedical microdevices 16.1 (2014): 91-96.‏
45.Tan, Say Hwa, et al. “Oxygen plasma treatment for reducing hydrophobicity of a sealed polydimethylsiloxane microchannel.” Biomicrofluidics 4.3 (2010): 032204.
46.Pun, Sirjana, Li Cai Haney, and Riccardo Barrile. “Modelling Human Physiology on-Chip: Historical Perspectives and Future Directions.” Micromachines 12.10 (2021): 1250.